Jove
Visualize
Contact Us

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gaps, Barriers, and Facilitators to Implementing Comprehensive Medication Management in Cardiovascular-Kidney-Metabolic Care: A Qualitative Study.

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

A Scoping Review of Pharmacist-Based Interprofessional Interventions for Management of Cardiovascular-Kidney-Metabolic Conditions.

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

Optimizing Comprehensive Medication Management in CKD: An Opportunity to Integrate Pharmacists in the Kidney Care Team.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2025
Same author

A Systematic Literature Review of Coordinated Care in Cardiovascular-Kidney-Metabolic Conditions.

Mayo Clinic proceedings. Innovations, quality & outcomes·2025
Same author

Comment on "Establishing discordance rate of estimated glomerular filtration rate between serum creatinine-based calculations and cystatin-C-based calculations in critically ill patients".

Pharmacotherapy·2025
Same author

Perspectives of medication-related experiences in Black persons with kidney diseases: The patient voice.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 8, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

Chronic kidney disease and medicare.

Wendy L St Peter1

  • 1College of Pharmacy at the University of Minnesota, Minneapolis, MN 55404, USA. WStPeter@nephrology.org

Journal of Managed Care Pharmacy : JMCP
|February 22, 2008
PubMed
Summary

Medicare Part D presents challenges for end-stage renal disease (ESRD) patients, particularly dual-eligible individuals. Pharmacists can help optimize medication therapy management (MTM) for these complex patients.

Area of Science:

  • Nephrology
  • Health Policy
  • Pharmacology

Background:

  • Medicare has covered end-stage renal disease (ESRD) costs since 1972, with employer plans previously covering most prescription expenses.
  • The implementation of Medicare Part D has created significant hurdles for ESRD patients accessing prescription drug benefits.
  • Understanding Medicare Part D is crucial for addressing the unique challenges faced by the ESRD population.

Purpose of the Study:

  • To analyze the implications of Medicare Part D for chronic kidney disease (CKD) populations.
  • To identify challenges faced by ESRD patients in navigating Part D prescription drug coverage.
  • To explore potential solutions, including managed care and medication therapy management (MTM), for improving care and reducing costs.

Main Methods:

More Related Videos

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

Related Experiment Videos

Last Updated: Jul 8, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

  • Review of Medicare Part D coverage and its impact on ESRD patients.
  • Analysis of medication coverage divides between Medicare Part B and Part D.
  • Examination of issues specific to dialysis patients and comorbid conditions.
  • Evaluation of managed care demonstration projects and MTM services.
  • Main Results:

    • Approximately 405,000 ESRD patients were eligible for Part D in 2006.
    • The division of drug coverage between Medicare Part B and Part D is confusing for clinicians and patients.
    • Dual-eligible ESRD patients face challenges with Prescription Drug Plan (PDP) formularies potentially lacking necessary medications.
    • ESRD patients often have multiple comorbidities, making them candidates for MTM services.

    Conclusions:

    • Medicare Part D has unique implications for CKD patients, including those on dialysis, post-transplant, and not on dialysis.
    • Managed care models and MTM services offer opportunities to improve care quality and efficiency for ESRD patients.
    • Healthcare providers should actively assist CKD patients in selecting appropriate formularies.
    • Pharmacists have a key role in providing MTM services to ESRD patients, optimizing their medication regimens.